Juluca is a fixed-dose combination tablet containing two anti-HIV drugs, dolutegravir and rilpivirine. Juluca is manufactured and marketed by ViiV Healthcare.

Dolutegravir is an integrase inhibitor also marketed alone as Tivicay and combination with lamivudine and abacavir as Triumeq. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) also marketed alone as Edurant, in combination with tenofovir disoproxil and emtricitabine as Eviplera and in combination with tenofovir alafenamide and emtricitabine as Odefsey.

Juluca is licensed for the treatment of HIV in people who already have an undetectable viral load for six months and no resistance to integrase inhibitors or NNRTIs. Juluca does not need to be combined with other anti-HIV drugs.

Juluca was approved in the United States in November 2017 and in the European Union in May 2018. Juluca was approved on the basis of results from the SWORD 1 & 2 studies, in which 1024 adults with viral load < 50 copies/ml were randomised to continue their existing antiretroviral regimen or switch to Juluca. After 48 weeks there was no significant difference in the proportions with undetectable viral load (95% in each arm).1

Juluca is taken as one pink tablet once a day with food. Juluca contains 50mg of dolutegravir and 25mg of rilpivirine. An additional dose of 25mg of rilpivirine should be taken as a separate tablet when Juluca is taken at the same time as treatment with rifabutin.

Common side-effects of Juluca include:

  • difficulty in sleeping, abnormal dreams, depression, depressed mood, anxiety, headache, dizziness, drowsiness, fatigue
  • nausea, diarrhoea, abdominal pain, vomiting, flatulence, dry mouth, decreased appetite
  • increased liver enzymes or bilirubin or creatinine phosphokinase or lipase or pancreatic amylase
  • decreased white blood cell count, haemoglobin or platelet count, increased total or LDL cholesterol, increased triglycerides
  • rash, itching.

You should not take Juluca if you are currently taking medicines from the following groups:

  • products that contain St John’s wort (a herbal remedy used for depression and anxiety)
  • rifampicin and rifapentine (used to treat some bacterial infections such as tuberculosis)
  • carbamazepine, oxcarbazepine, phenobarbital and phenytoin (used to treat epilepsy and prevent seizures)
  • proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole (used to treat acid reflux)
  • systemic dexamethasone (anti-inflammatory steroid, many uses for treatment of serious conditions)
  • dofetilide (treatment for irregular heartbeat).

H2-recepter antagonists such as famotidine, used to reduce the amount of stomach acid, should be taken at least 4 hours after or 12 hours before Juluca.

Antacids containing magnesium should be taken at least 6 hours before or 4 hours after Juluca.

Calcium supplements, iron supplements or multivitamins should be taken at the same time as Juluca, with a meal.

Juluca is not recommended for women who are pregnant or who might become pregnant. Juluca should be used with effective contraception. Juluca is not recommended if you are breastfeeding.

For further information about side-effects and drug resistance, see entries for the individual agents dolutegravir and rilpivirine.


  1. Llibre JM et al. Phase III SWORD 1&2: switch to DTG+RPV maintains virologic suppression through 48 wks. Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 44LB, February 13-16, 2017
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.